The stock is in a deep downtrend, with a 1-year price change of -44.5% and currently trading at $42.57, near the bottom of its 52-week range of $37.08 to $87.03 (approximately 11% above the low). This positioning near the low suggests the stock is deeply oversold but also reflects a 'falling knife' scenario where value investors may be cautious. The 52-week high of $87.03 represents a 104% premium to the current price, indicating the extent of the decline. Short-term momentum remains negative, with a 1-month price change of -17.8% and a 3-month change of -26.5%, both accelerating to the downside. The relative strength versus the S&P 500 is extremely weak, with a 1-month relative strength of -21.9% and a 1-year relative strength of -65.1%, confirming the stock is underperforming the market by a wide margin. The 1-month trend aligns with the longer-term downtrend, showing no signs of reversal. Key support lies at the 52-week low of $37.08, while resistance is at the 52-week high of $87.03. A breakdown below $37.08 would signal further downside, while a move above $87.03 would require a massive reversal. The stock's beta of 0.86 indicates it is less volatile than the market, but the recent price action shows extreme downside volatility, with a maximum drawdown of -55.3% over the period.

Revenue growth has been modest but decelerating. In Q4 2025, revenue was $5.33 billion, up 4.9% year-over-year, but this growth rate is below the 6.5% seen in Q1 2025 and the 7.1% in Q2 2025. The largest revenue segment is Healthcare at $1.62 billion, followed by Financial Services at $1.59 billion, Products and Resources at $1.32 billion, and Communication, Media and Technology at $0.81 billion. The deceleration suggests headwinds in discretionary IT spending and competitive pressures. Profitability remains solid but margins are under pressure. Net income in Q4 2025 was $648 million, with a net margin of 12.2%, down from 13.0% in Q1 2025. Gross margin has declined from 33.6% in Q1 2025 to 31.1% in Q4 2025, reflecting higher cost of revenue and pricing competition. Operating margin also compressed from 16.7% to 16.0% over the same period. The balance sheet is healthy with a debt-to-equity ratio of 0.10 and a current ratio of 2.34, indicating low leverage and ample liquidity. Free cash flow for the trailing twelve months is $2.60 billion, providing a free cash flow yield of 6.5% based on the current market cap. ROE stands at 14.9%, which is respectable for the IT services industry. The company generates sufficient cash to fund operations and dividends, with a payout ratio of 27.4%.